A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
US2018200209A1
Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride
WO2016164476A2
Combination of an acat1 inhibitor and a cyp1 1 b1 inhibitor for treating disorders associated with excess cortisol production
MX2017003916A
Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(di methylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto.
MX2014011188A
Compounds and methods for treating aberrant adrenocartical cell disorders.
